Is Jazz Pharmaceuticals plc (JAZZ) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 48.4% / 30% | 21.8% / 30% | 7.4% / 30% | 22.27% / 5% | ✗ NOT HALAL |
| DJIM | 48.4% / 33% | 21.8% / 33% | 7.4% / 33% | 22.27% / 5% | ✗ NOT HALAL |
| MSCI | 46.5% / 33% | 20.9% / 33% | 7.1% / 33% | 22.27% / 5% | ✗ NOT HALAL |
| S&P | 48.4% / 33% | 21.8% / 33% | 7.4% / 33% | 22.27% / 5% | ✗ NOT HALAL |
| FTSE | 46.5% / 33% | 20.9% / 33% | 7.1% / 50% | 22.27% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 91.7% | |
| Operating Margin | 27.1% | |
| Net Margin | -8.3% | |
| Return on Equity (ROE) | -8.5% | |
| Return on Assets (ROA) | 5.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1.4B |
| Free Cash Flow | $1.1B |
| Total Debt | $5.4B |
| Debt-to-Equity | 125.7 |
| Current Ratio | 1.9 |
| Total Assets | $11.7B |
Price & Trading
| Last Close | $189.15 |
| 50-Day MA | $175.73 |
| 200-Day MA | $145.91 |
| Avg Volume | 998K |
| Beta | 0.2 |
|
52-Week Range
$95.49
| |
About Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Jazz Pharmaceuticals plc (JAZZ) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Jazz Pharmaceuticals plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Jazz Pharmaceuticals plc's debt ratio?
Jazz Pharmaceuticals plc's debt ratio is 48.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 46.5%.
What are Jazz Pharmaceuticals plc's key financial metrics?
Jazz Pharmaceuticals plc has a market capitalization of $11.2B, and revenue of $4.3B. The company maintains a gross margin of 91.7% and a net margin of -8.3%. Return on equity stands at -8.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.